Painreform Ltd

PRFX · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

0.7826USD-0.00 (-0.53%)

Price History

Full chart

Market Stats

Previous Close0.7868

Open0.7383

Day Range0.6973 – 0.8658

52-Week Range0.8519 – 7.95

Volume352.61K

Market Cap3.42M

P/E (TTM)0.00

Forward P/E0.00

EPS-4.09

Dividend Yield0.00%

Beta1.04

50-Day Avg1.02

200-Day Avg2.27

About

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Efraim Cohen-Arazi
Employees6
Headquarters65 Yigal Alon St., Tel Aviv, Israel, 6744316, USA
Websitehttps://www.painreform.com

Leadership

Dr. Ehud Geller Ph.D.Executive Chairman
Mr. Eyal BroderChief Financial Officer · b. 1971
Dr. Sigal Aviel eMBA, Ph.D.Chief Operating Officer · b. 1964
Mr. Efraim Cohen-AraziInterim CEO & Director · b. 1955
Ms. Rita Keynan M.Sc.Vice President of Pharmaceutical Operations · b. 1969

Financials

Income Statement

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	0	0	0	0	86.00K	0	0	17.00K
Growth (%)	-	-	-	-	-	-	-100.00%	-	-
Cost of Revenue	-	-	1.00K	-	7.00K	15.00K	15.00K	16.00K	844.00K
Gross Profit	-	-	-1.00K	-	-7.00K	71.00K	-15.00K	-16.00K	-827.00K
Gross Margin	-	-	-	-	-	82.56%	-	-	-4864.71%
Operating Expense	-	-	688.00K	-	7.20M	8.94M	9.57M	14.66M	4.16M
Operating Income	-880.00K	-500.00K	-689.00K	-1.67M	-7.21M	-8.87M	-9.58M	-14.67M	-4.99M
Operating Margin	-	-	-	-	-	-10312.79%	-	-	-29335.29%
EBITDA	-1.21M	-501.00K	-688.00K	-1.67M	-7.20M	-8.76M	-9.57M	-14.55M	-4.21M
EBITDA Margin	-	-	-	-	-	-10180.23%	-	-	-24782.35%
Net Income	-2.09M	-828.00K	-1.82M	-4.05M	-7.25M	-8.79M	-9.34M	-14.59M	-4.84M
Net Income Margin	-	-	-	-	-	-10223.26%	-	-	-28458.82%
R&D	504.00K	223.00K	136.00K	354.00K	2.86M	4.42M	6.04M	11.71M	1.14M
R&D as % of Total Revenue	-	-	-	-	-	5141.86%	-	-	6682.35%
Interest Expense	0	324.00K	541.00K	987.00K	10.00K	61.00K	384.00K	14.00K	10.00K
Interest Expense % of Total Revenue	-	-	-	-	-	70.93%	-	-	58.82%

Balance Sheet

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	214.00K	81.00K	1.16M	17.80M	19.07M	12.33M	9.93M	4.53M	12.00M
Total Liabilities	3.84M	4.54M	6.79M	1.18M	991.00K	1.31M	2.69M	2.70M	2.71M
Total Equity	-3.63M	-4.46M	-5.62M	16.62M	18.08M	11.02M	7.24M	1.82M	8.54M
Cash	187.00K	40.00K	941.00K	15.68M	16.54M	4.10M	8.03M	4.26M	4.17M
Total Debt	3.71M	4.52M	6.17M	-	-	-	86.00K	45.00K	21.00K
Net Debt	3.52M	4.48M	5.23M	-15.68M	-16.54M	-4.10M	-7.94M	-4.22M	-4.14M

Cash Flow

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-870.00K	-635.00K	-609.00K	-2.56M	-6.55M	-6.46M	-6.68M	-12.62M	-3.96M
Investing Cash Flow	-10.00K	-10.00K	-10.00K	-10.00K	-50.00K	-6.01M	5.99M	-13.00K	-982.00K
Financing Cash Flow	699.00K	488.00K	1.51M	17.31M	7.48M	0	4.62M	8.86M	3.82M
Capital Expenditure	10.00K	10.00K	10.00K	10.00K	50.00K	6.00K	9.00K	13.00K	2.00K
Free Cash Flow	-870.00K	-635.00K	-609.00K	-2.57M	-6.60M	-6.46M	-6.69M	-12.63M	-3.96M
FCF to OCF	100.00%	100.00%	100.00%	100.39%	100.76%	100.09%	100.13%	100.10%	100.05%

Earnings

Report Date	Mar 31, 2018	Jun 30, 2018	Sep 30, 2018	Dec 31, 2018	Mar 31, 2019	Jun 30, 2019	Sep 30, 2019	Dec 31, 2019	Feb 3, 2020	Jun 30, 2020	Sep 2, 2020	Dec 2, 2020	Mar 18, 2021	May 13, 2021	Aug 16, 2021	Nov 15, 2021	Mar 17, 2022	May 16, 2022	Aug 15, 2022	Nov 14, 2022	Mar 15, 2023	May 16, 2023	Aug 10, 2023	Nov 15, 2023	Feb 29, 2024	May 15, 2024	Aug 15, 2024	Nov 12, 2024	Mar 31, 2025	Apr 7, 2025	Aug 29, 2025	Nov 27, 2025
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-102.00	-16.20	-6.60	-672.00	-612.00	-516.00	-0.55	-672.00	-192.00	-204.00	-180.00	-0.32	-300.00	-168.00	-1.49	-288.00	-124.80	-4.74	-7.68	-7.68	0.00	0.00
EPS Actual	-0.80	-0.80	-0.82	-0.82	-0.85	-0.85	-1.24	-1.24	-0.10	-0.21	-408.00	-0.27	0.00	-276.00	-192.00	-216.00	-0.17	-192.00	-204.00	-240.00	-348.00	-0.22	-230.40	57.60	-3.11	-326.40	-48.00	-18.96	-2.32	-2.32	-1.09	0.00
Surprise	-	-	-	-	-	-	-	-	-	-	-300.00%	98.33%	100.00%	58.93%	68.63%	58.14%	69.09%	71.43%	-6.25%	-17.65%	-93.33%	31.25%	23.20%	134.29%	-108.72%	-13.33%	61.54%	-300.00%	69.79%	69.79%	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	After-hours	Pre-market	Pre-market	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	-	-	-	-	-

Key Statistics & Ratios

Market Cap3.42M

Enterprise Value-7.93M

Trailing P/E0.00

Forward P/E0.00

Price / Sales110.25

Price / Book0.22

EPS-4.09

Book Value5.22

Revenue (TTM)31.00K

Gross Profit (TTM)-95.00K

EBITDA-4.24M

Profit Margin0.00%

Operating Margin-18114.29%

Return on Equity-45.33%

Return on Assets-21.88%

Shares Outstanding3.50M

Shares Float3.04M

Beta1.04

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Hold

Based on 1 analystsTarget 12.00

Hold
1

Ownership Breakdown

Institutions: 6.69%
Insiders: 6.58%
Retail / Other: 86.73%

Top Institutional Holders

Yorkville Advisors Global, LP
81.10K2.67%
Citadel Advisors Llc
28.57K0.94%
Morgan Stanley - Brokerage Accounts
1.61K0.05%
UBS Group AG
8690.03%
Advisor Group Holdings, Inc.
400.00%
SBI Securities Co Ltd
00.00%
XTX Topco Ltd
00.00%
TWO SIGMA SECURITIES, LLC
00.00%

Top Fund Holders

Fidelity Nasdaq Composite Index
3190.01%

Stock Splits

Feb 6, 20261:5
Sep 9, 20241:6
Jul 3, 20231:10